Premium
Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11 C‐N‐methyl‐spiperone
Author(s) -
Hägglund J.,
Aquilonius SM,
Eckernäs SA,
Hartvig P.,
Lundquist H.,
Gullberg P.,
Längström B.
Publication year - 1987
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1987.tb07900.x
Subject(s) - putamen , spiperone , dopamine , striatum , dopamine receptor d2 , radioligand , dopaminergic , dopamine receptor , caudate nucleus , chorea , medicine , endocrinology , chemistry , positron emission tomography , huntington's disease , temporal cortex , receptor , nuclear medicine , neuroscience , psychology , disease
— Dopaminergic receptor properties in the striatum of patients with Parkinson s disease (PD) and Huntington's chorea (HD) were studied by positron emission tomography (PET), using 11 C‐N‐methyl‐spiperone as a dopamine D 2 receptor ligand. The time‐dependent regional radioactive uptake in the caudate nucleus and the putamen was measured and fitted to a 3‐compartment pharmacokinetic model. The rate constant k 3 for specific binding to the receptor compartment in the striatum was determined in relation to the binding in regions with a low density of specific binding sites, such as the cerebellum and the frontal cortex–k 3 , which is a measure of the receptor density, was reduced in one patient with HD but less affected in PD in comparison with healthy controls. The pattern of k 3 values calculated from the 6 PD patients is discussed in relation to any side‐to‐side differences in dopamine receptor densities in hemiparkinsonism and to possible “hypersensitivity” of dopamine receptors in the early stage of the disease and down‐regulation in more advanced disease.